Corporate News

Ora will provide clinical development and regulatory consulting services to the collaboration.
For over 10 years the FDA has been accepting electronic submissions of regulatory documents.
May Offer Faster, More Effective, Longer Lasting Relief
A sterile, preservative-free eye drop, to evaluate its safety and efficacy for the treatment of signs and symptoms of dry eye
Double-masked Phase 2 trial to evaluate the safety and efficacy of RGN-259 as a treatment of dry eye syndrome
SAR 1118 is a first-in-class molecule that inhibits T-cell inflammation by blocking the binding of two key cellular surface proteins
Firms in addition ink manufacturing agreement for one of Aciex's lead prescription candidates.
Ora operates a clinical research facility and a large international investigator network.

Pages

Subscribe to Corporate News